Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dihydroartemisinin for PCOS
NCT06842524Phase 2Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Apr 2025
- Primary completion
- Sep 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in polycystic ovary syndrome (PCOS) comparing Dihydroartemisinin Arm with Placebo Arm (2 arms). Primary endpoint: Occurrence of a regular menstrual cycle at 26 weeks. Started Apr 2025; status: recruiting.
02
Drugs
dihydroartemisinin
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT06842524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06842524.